Polarean Imaging Limited

M2M ImagingPolarean Imaging Limited Polarean’s technology enables the visualisation of hyperpolarised 129Xenon via magnetic resonance imaging technology.  Polarean is a clinical stage, revenue generating medical imaging product company that expects to gain clinical approval for its drug/device combination product within three years.  The protocol for the Phase III clinical trial has been agreed with the FDA and, if successful, should garner a broad clearance to market “for use in pulmonary medicine”. Polarean is planning to hold the trial at two sites, each of which already has at least one polariser, namely Duke University and the University of Virginia.  The company expects to start the clinical trial at the beginning of 2018.  Polarean continues to sell its polariser units and consumables to leading research institutions and plans to continue do so while the Phase III clinical trial is underway. 

M2M Imaging


C. Richard Hullihen - Chief Executive Officer
Bastiaan Driehuys - Founder and Chief Scientific Officer
Kenneth West - Chief Operating Officer
William Patrick - Controller

Board of Directors

Richard C.E. Morgan - (Chairman) Chief Executive Officer, Amphion Innovations
Jonathan Allis - CoFounder and Chief Executive Officer, Blue Earth Diagnostics
Robert J. Bertoldi - President and Chief Financial Officer, Amphion Innovations
Bastiaan Driehuys - Founder and Chief Scientific Officer, Polarean Imaging Limited
C. Richard Hullihen - Chief Executive Officer, Polarean Imaging Limited
Juergen Laucht - Managing Director, Nukem Isoptopes
Kenneth West - Chief Operating Officer, Polarean Imaging Limited



Top of page